BANK VONTOBEL/CALL/BIONTECH ADR/110/0.1/20.09.24 Share Price

Warrant

DE000VM31DC1

Market Closed - Deutsche Boerse AG 19:02:28 28/06/2024 BST
0.044 EUR -4.35% Intraday chart for BANK VONTOBEL/CALL/BIONTECH ADR/110/0.1/20.09.24
Current month-91.37%
1 month-82.40%
Date Price Change
28/06/24 0.044 -4.35%
27/06/24 0.046 -19.30%
26/06/24 0.057 -24.00%
25/06/24 0.075 -12.79%
24/06/24 0.086 +17.81%

Delayed Quote Deutsche Boerse AG

Last update June 28, 2024 at 07:02 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
WKN VM31DC
ISINDE000VM31DC1
Date issued 16/10/2023
Strike 110 $
Maturity 20/09/2024 (84 Days)
Parity 10 : 1
Emission price 1.42
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.84
Lowest since issue 0.044
Spread 0.01
Spread %17.54%

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
75 EUR
Average target price
103.5 EUR
Spread / Average Target
+38.03%
Consensus